Purpose of review To summarize the most recent preclinical and clinical advancements in therapeutic nano-oncology.
INTRODUCTION
Cancer is the second leading cause of mortality in the United States [1] . Longstanding efforts to develop biological and small molecule cancer therapies continue to produce new drugs, but at everincreasing cost and reduced efficiency [2] . New opportunities need to be explored to increase the number of new drugs that make it to the clinic. Nanotechnology, the science of materials with size dimensions between 1 and 100 nm, is having a significant impact on the treatment of cancer. This review provides a brief overview of the potential and realized benefits of nanoparticle-based therapies and, because of length restrictions, a focused summary of the recent advancements in standalone nanoparticle drugs and drug-carrier combinations that are systemically administered to treat cancer. Therapies based upon nanoparticles are FDA approved, whereas more sophisticated next-generation designs are being developed and introduced into the clinic. This article also highlights some preclinical developments in nanoparticle therapies to illustrate their continued and, likely, increased presence in cancer drug development pipelines.
FEATURES OF NANOPARTICLE DRUGS
Nanoparticle drugs are, typically, between 10 and 100 nm in diameter. The 10-nm lower limit is because nanoparticles smaller than 10 nm can be filtered by the kidney and excreted in the urine [3] .
The vast majority of current nanoparticle therapies for cancer, with some highlighted exceptions, are comprised of therapeutic molecules (e.g. small molecules, nucleic acids, etc.) that self-assemble with lipids or polymers into nanostructures [4] [5] [6] . There are many perceived benefits of nanoparticles; however, one critical benefit that has been realized in the clinic is a reduction in the side-effect profile of nanoparticle formulations of otherwise toxic chemotherapeutics. This is mostly achieved through drug targeting, either passive or active, by nanoparticles. Passive targeting is believed to result from the small size of nanoparticles and the enhanced permeation and retention (EPR) effect whereby solid tumors display increased vascularization and permeability, resulting in greater nanoparticle accumulation in the interstitial tumor space compared with normal, healthy tissue [7] . Although the EPR effect has been exploited to target tumor cells preclinically, the heterogeneity of solid tumors may limit the effectiveness of EPR-based nanoparticle therapeutics in humans and has been the topic of intense recent investigation [8] . It is becoming clearer that a variety of factors influence the EPR effect and nanoparticle accumulation in tumors such as tumor vasculature, blood pressure, and tumor type (primary vs. metastatic lesion) and location. For active targeting, nanoparticles can be endowed with surface ligands that specifically bind to cancer cells. A prominent clinical example of an active targeting ligand, although not the first or only example, is transferrin (Tf), the 80-kDa glycoprotein responsible for delivering iron to cells. The transferrin receptor (TfR) is highly expressed on the surface of many cancer cells [9] ; therefore, incorporation of Tf in nanoparticle formulations allows for preferential uptake.
Also, nanoparticles are tailorable such that they can be synthesized to bind and stabilize difficult-toformulate hydrophobic drugs or ones that require enhanced stabilization, such as nucleic acid-based therapies [e.g. short interfering RNAs (siRNA)]. With regard to nucleic acids, nanoparticles are playing a pivotal role in bringing this exciting class of therapeutic molecules to clinical reality because of the ability of nanoparticles to carry nucleic acids, stabilize them against nuclease degradation, and target their delivery to appropriate cell types. Tailorability not only allows one to incorporate diverse drugs, but also provides an opportunity for multifunctionality in the form of targeting, multiple drug loading, or the addition of molecules that provide image contrast.
In short, nanoparticles can be functionalized with diverse molecular payloads and can preferentially deliver therapies to malignant cells while minimizing exposure to healthy tissue. As discussed below, these attributes are currently being realized in clinical trials and in preclinical development of next-generation nanotherapies.
PASSIVELY TARGETED NANOPARTICLES AND SMALL MOLECULES
Several nanoparticle-based drugs have moved into the clinic [10] . Two well known passively targeted nanoparticle therapies are Doxil and Abraxane. Doxil is a liposomal drug containing doxorubicin and Abraxane is a formulation of paclitaxel and albumin. The nanoparticles help improve the solubility of the chemotherapeutics, allow them to remain in circulation longer, and ameliorate some of the adverse side-effects of the free drugs. Doxil has been approved for treating ovarian cancer, and recent clinical trials have been focused on combinational therapies with efficacy seen when Doxil is combined with panitumumab to treat platinumresistant epithelial ovarian cancer [11] ; with rituximab, cyclophosphamide, vincristine and prednisone in AIDS-related lymphoma [12] ; and with cisplatin in malignant pleural mesothelioma [13] . Abraxane, currently used to treat metastatic breast cancer [14] and ovarian cancer [15] , is finding clinical success against pancreatic cancer [16] , nonsmall cell lung carcinoma [17] and drug-resistant metastatic cervical cancer [18] .
Further, a recently developed self-assembled polymeric nanoparticle containing the topoisomerase I inhibitor camptothecin, called CRLX101 (formerly IT-101), has shown efficacy in phase I/IIa clinical trials in a variety of solid tumor malignancies, including nonsmall cell lung cancers [19 & ].
Camptothecin is most efficacious when applied continuously to the tumor cells; however, prolonged exposure is associated with severe bone marrow suppression and hemorrhagic cystitis.
KEY POINTS
Clinical trials have demonstrated that nanoparticlebased therapies are effective treatments for a variety of cancers and can reduce the side-effect profiles of chemotherapeutics.
Nanoparticles are being used to deliver increasingly sophisticated cargoes including small molecules, nucleic acids, peptides, proteins, and combinations of these molecules to cancer cells in vitro and in vivo.
Biomimetic nanostructures may represent a paradigm shift in nanotherapeutics because of their inherent, novel functions, and targeting abilities.
Incorporating camptothecin into polymeric nanoparticles improves delivery to solid tumor cells and was well tolerated in patients [19 & ].
ACTIVELY TARGETED NANOPARTICLES AND SMALL MOLECULES
Prostate-specific membrane antigen (PSMA) is presented exclusively on prostate cancer cells and tumor-associated endothelial cells [20] . A short PSMA-targeting peptide, which binds to the extracellular domain of PSMA, was incorporated into a polymer-based nanoparticle encapsulating docetaxel (DTXL-TNP). In preclinical data, DTXL-TNP demonstrated prolonged circulation, controlled release of docetaxel, and minimal liver accumulation in mice and nonhuman primates [ 
NANOPARTICLES AND NUCLEIC ACID DELIVERY
Nucleic acids, such as siRNAs, have long been studied as cancer therapies based upon their tremendous versatility and target specificity [22] . However, delivery of sufficient quantities of siRNAs to achieve target gene knockdown as a therapy for cancer is a major challenge. Nanoparticles have the potential to deliver therapeutic doses of nucleic acids to tumor cells. Critical to the design of these nanoparticles is the need for nucleic acids to avoid endosomal sequestration in order for them to reach the cytoplasm of targeted cancer cells, where the mRNA target resides.
The nanostructure CALAA-01, consisting of a cyclodextran polymer, an siRNA targeted against the M2 subunit of ribonucleotide reductase (RRM2) and Tf, serves as an excellent example of a TfR-targeted nanoparticle for delivering siRNA. Also, CALAA-01 has imidazole residues, a sink for protons in acidified endolysosomes, which can lead to endosomal disruption and siRNA release into the cytoplasm of target cells [23] . In a groundbreaking clinical trial, systemic administration of CALAA-01 to patients with solid tumors led to accumulation of CALAA-01 in tumor tissues, delivery of functional siRNA, and knockdown of RRM2 at both the mRNA and protein level [24 & ]. This is the first published report of RNAi occurring in humans and strongly supports the concept of siRNA-based cancer therapeutics. Additionally, CALAA-01 is a relatively complex nanoparticle formulation and demonstrates how such entities can be successfully moved to the clinic [25] .
Lipid . ALN-VSP was well tolerated by patients, who had at least one measureable tumor in the liver, and treatment resulted in the knockdown of target genes in the liver tissue.
BEYOND LIPID AND POLYMER-BASED NANOPARTICLES
Lipid and polymer-based nanoparticles and microparticles have run the gauntlet of development, approval, and clinical use faster than other nanoparticles, such as those based upon noble metals or other scaffolding nanomaterials. However, these nanoparticles are also making their way into the clinic. One recent clinical example is the use of gold nanoparticles (AuNP) to deliver the vascular disrupting agent (VDA) tumor necrosis factor-alpha (TNF-a). Currently, VDAs are hampered by doselimiting side effects such as systemic hypotension and cardiotoxicity. Conjugation of TNF-a to AuNPs (NP-TNF) improves tolerance in a mouse model by passively targeting the therapy to tumors and effectively disrupting tumor vasculature, enabling synergistic thermal therapies to decrease tumor volume [28 & ]. Conjugation of polyethylene glycol to the AuNPs reduced clearance by the reticuloendothelial system [29] . Phase I clinical trial data demonstrated that systemic NP-TNF administration results in a TNF-a concentration that is three times as high as when TNF-a is given alone with no maximal tolerable dose achieved, suggesting that nanoparticle formulation of TNF-a significantly mitigated the adverse effects of systemic administration [29] . This study demonstrates that AuNPs are making their way into the clinic as a component of a systemically administered therapy that may provide a new and effective therapeutic opportunity for patients with cancer.
PRECLINICAL NANOPARTICLE-BASED THERAPEUTICS
As nanoparticle-based therapeutics begin to have an impact in the clinic, exciting new nanostructures are being developed to improve therapeutic delivery and expand on the potential uses of nanotechnology in medicine.
Novel delivery
Whereas most nanoparticle therapies are aimed at systemic administration, overcoming the physical barriers to drug delivery, such as the blood-brain barrier (BBB) and the stratum corneum of the skin, can provide critical new opportunities for cancer therapy. Some recent examples demonstrate that nanoparticles may provide ways to overcome these barriers. For instance, to improve delivery of nanoparticles to the brain, AuNPs were surface-functionalized with Tf, which aided in shuttling the particles across the BBB via receptor-mediated transcytosis [30 & ]. Also, in a preclinical model, AuNPs surfacefunctionalized with siRNAs, termed spherical nucleic acid nanoparticle conjugates (SNA-NCs), were able to fully penetrate mouse and human epidermal layers without additional agents needed to disrupt the stratum corneum, and with no observed toxicity [31 && ]. These SNA-NCs delivered functional siRNAs against epidermal growth factor receptor (EGFR), resulting in decreased EGFR expression and epidermal thickness in a mouse model [31 && ]. These examples demonstrate that nanoparticles will play an ever-increasing role in the delivery of therapeutics, in some cases, overcoming the significant barriers that have traditionally been quite difficult to circumvent.
Targeted drug delivery
Preclinical research has focused on delivering an assortment of current chemotherapeutic drugs to cancer cells using targeted nanoparticle platforms. In addition to doxorubicin and paclitaxel, nanoparticle-based delivery of gemcitabine [32] , docetaxel [33] , and cisplatin and irinotecan [34] has demonstrated promising results in the preclinical setting, ameliorating the associated adverse effects and enhancing the drug efficacy. A myriad of targeting moieties have been investigated for their ability to direct nanoparticles to tumor sites, including the HER2 monoclonal antibody Herceptin [35, 36] , folate [37] , and aptamers [33, 38, 39] . Additional work has focused on enhancing the penetration, retention, and release of therapeutic cargo of nanoparticle-based therapeutics in cancer cells by taking advantage of the relatively low pH and increased protease expression in the tumor microenvironment. For instance, matrix metalloproteinase-2-sensitive molecules [40] , pH-sensitive linkers [41] , and ester linkages [42] have been utilized to improve uptake and drug delivery to tumor cells.
Nucleic acid delivery
Preclinical investigations have utilized polymeric [43] [44] [45] and DNA-based [46] nanoparticles to deliver siRNAs to tumor cells. Additionally, lipoproteins have been investigated as delivery vehicles for siRNAs modified with lipophilic moieties. Looking beyond the LDLR, HDLs have been shown to bind and stabilize native [47] and lipophilic nucleic acids [26] , and are emerging as potent nucleic acid delivery vehicles because of their targeting of scavenger receptor type B-1 (SR-B1) expressed by the cancer cells. Numerous tumor cell types express SR-B1 [48, 49] . Surface functionalization of 5-nm AuNPs with apolipoprotein-A1 (ApoA1) and phospholipids resulted in HDL nanoparticles (HDL-NPs) with similar size, shape, and surface chemistry to natural, mature, spherical HDLs [50,51,52
&& ]. Cholesterylated nucleic acids adsorbed to HDLNPs were shown to be resistant to nuclease degradation [52 && ]. Treatment of prostate cancer cells with these conjugates resulted in decreased target gene expression, with data suggesting that the HDL-like delivery vehicle provided a means to avoid endolysosomal sequestration of therapeutic nucleic acids [52 && ]. Further, incorporation of siRNAs into reconstituted HDL (rHDL), consisting of ApoA1 and phospholipids around a core of siRNA and a templating polymer, yielded rHDL nanoparticles capable of delivering siRNA to silence target genes in vivo [47] . Finally, lipid nanoparticles containing siRNA targeted against the androgen receptor achieved knockdown in human prostate cancer cells both in vitro and in tumor xenografts [54 & ].
NOVEL BIOMIMETIC NANOPARTICLE CANCER THERAPIES
Whereas most nanoparticle research has been aimed at using nanostructures as drug delivery vehicles, In addition to lipoproteins, exosomes are 30-100-nm nanovesicles produced by all cells and responsible for the intercellular trafficking of biological material like nucleic acids and proteins [55] .
Researchers have begun to engineer exosomes for the targeted delivery of siRNA for gene regulation [56 & ]. For instance, mouse dendritic cells were engineered to produce exosomes with a brain targeting protein fused to LAMP2b, an essential component of exosomes. The engineered exosomes were loaded with siRNAs targeting beta-secretase 1 using electroporation and then systemically administered to animals. Treatment resulted in knockdown of beta-secretase 1 expression in the brain. In another study, exosomes derived from the bone marrow stromal cells were engineered to contain miR146b. Treatment of rats with primary brain tumors resulted in significantly reduced growth of glioma cells [57] . These results expand on the idea of studying endogenous nanostructures to aid in the design of new therapeutics for cancer.
CONCLUSION
Nanotechnology is having a significant impact in medicine. Nanoparticle anticancer agents have been used in the clinic for some time and there are clear advantages of nanoparticles with regard to reducing the side-effects of drug cargo, enhanced tumor targeting, and, in some cases, therapeutic efficacy. Newer nanoparticles with increased active tumor cell targeting properties are making their way into clinical trials. Thus, the armamentarium of approved nanoparticle drugs will certainly increase as regulatory agencies and clinicians become more familiar with their safety profiles and efficacy. The preclinical literature is replete with the examples of nanostructures that improve upon the properties of previous ones with regard to drug cargo, targeting, and reduced toxicity. Particular recent examples hint at the use of biomimetic, inherently functional nanostructures to derive therapeutic effects in cancer. Certainly, the need for new cancer therapies is significant and nanoparticle-based ones will find an ever-increasing presence in the clinic, hopefully, to the benefit of cancer patients across the spectrum of disease activity. The first report of dual RNAi in humans using siRNAs targeted against VEGF and KSP. These results demonstrate the feasibility of siRNA-based therapeutics in humans and in using a nanoparticle platform to deliver sufficient quantities of nucleic acids to decrease target expression at both the mRNA and protein level. 28.
